that releases photon energy that is easily measured noninvasively by BLI systems. 19, 21 Multiple models of cancer in animals have been developed to take advantage of this noninvasive way to measure deep-seated tumors (such as leukemia and gliomas), showing good correlation with tumor volume as assessed on other imaging modalities (computed tomography, MR imaging, and ultrasonography). 19 , 21 Here we describe a model of intracranial meningoma in mice that uses BLI to overcome the main obstacle in studying these tumors intracranially; that is, it enables sequential noninvasive tumor measurement in a cost-effective manner.
Materials and Methods

Meningioma Cell Cultures
The human immortal cell lines CH-157-MN and IOMM-Lee were grown in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, L-glutamine (2 M), penicillin (50 IU/ml), and streptomycin (50 mg/ml) at 37°C in 7.5% CO 2 .
9, 22 The CH-157-MN and IOMM-Lee cell lines were kind gifts of Dr. Yancey Gillespie (University of Alabama School of Medicine, Birmingham, Alabama) and Dr. Ian McCutcheon (University of Texas, M.D. Anderson Cancer Center, Houston, Texas), respectively.
The cell lines were grown to confluence in T-175 flasks and processed by the cytogenetics core facility at the University of Utah for Giemsa-band chromosome analysis.
Luciferase Transfection
The CH-157-MN and IOMM-Lee cells were plated at 10 5 cells per 10-cm dish and infected with a modified pMMP retrovirus fused with the coding sequences for luciferase and neomycin phosphotransferase (pMMP-LucNeo; a kind gift of Dr. Joshua Rubin, Washington University, St. Louis, Missouri) overnight in Optimem with 8 ng/ml hexadimethrine bromide (polybrene, Aldrich) and selected with G418, 300 mg/ml (Gibco), as described previously. 19 The reporter plasmid (pMMP-LucNeo) is under the control of a modified thymidine kinase promoter that constitutively expresses luciferase. In vitro luciferase expression was assessed after lysing 10 5 cells in 500 l of Glo Lysis buffer (Promega) for 10 minutes, adding 100 l of Brite Glo Luciferin (Promega), and assessing bioluminescence with a luminometer to confirm stable luciferase transfection.
In Vitro Growth Kinetics
Logarithmically growing CH-157-MN, CH-157-MN-LucNeo, IOMM-Lee, and IOMM-Lee-LucNeo cell lines were harvested and plated into 6-well plates at a density of 10 5 per well. Cell counts were accomplished for 3 days by harvesting the cells with trypsin and counting them using a bright-line hemocytometer. Cells were counted in triplicate for each time point.
Intracranial Tumor Implantation: Skull Base and Convexity Locations
All animal experiments were approved by the Animal Care and Use Committee of The University of Utah. The CH-157-MN-LucNeo and IOMM-Lee-LucNeo cell lines were harvested for intracranial xenografting after they had achieved logarithmic growth. Briefly, cells were grown to ~ 80% confluence in T-175 flasks. All steps were carried out on ice. Cell counts were determined by bright-line hemocytometer; cells were pelleted at 1000 rpm for 5 minutes at 4°C and resuspended in media to obtain the final cell concentration. Desired cell counts were 10 4 -10 6 cells per mouse resuspended in 3 l of growth medium.
Three-week-old immunodeficient mice (CD1, Charles River Laboratories) were anesthetized with intraperitoneal injections of 100 mg/kg ketamine and 10 mg/kg xylazine hydrochloride (both from Sigma,) in phosphate-buffered saline and placed in a mouse stereotactic head frame (David Kopf Instruments). For skull base locations, a 21-gauge needle was used to cannulate a bur hole in the frontal bone 3 mm anterior and 2 mm lateral to the bregma. The desired cell number was resuspended in 3 l of media and drawn into a 10-l Hamilton syringe (Hamilton), which was mounted onto the stereotactic mouse frame. Stereotactically, the needle was passed through the bur hole and slowly dropped to the floor of the middle fossa. The cell suspension was injected over 45 seconds, left in place for 30 seconds, and then withdrawn over 30 seconds. This process aids in preventing leakage of cells along the needle track. For convexity meningioma tumors, a similar technique was used; the anatomical landmarks are the same, and cells were infused stereotactically 2 mm below the frontal bone.
First, we xenografted varying numbers of CH-157-MN-LucNeo cells to the middle fossa skull base in each mouse: 10 4 cells in 15 mice, 10 5 in 10, 5 ϫ 10 5 in 5, and 10 6 in 15 mice. We used the IOMM-Lee-LucNeo cell line for middle fossa skull base experiments (10 5 cells in 13 mice and 5 ϫ 10 5 in 2). Finally, we xenografted CH-157-MN-LucNeo cells to the frontal cerebral convexity (5 ϫ 10 5 and 10 6 cells in 5 mice each). After the injections, the animals were given free access to water and examined twice a week. Any animals that showed illness or neurological deficits were killed in accordance with our institutional animal protocol. Tumors from all animals were harvested at the time of death for paraffin blocks and electron microscopy.
Intracranial BLI
Luciferase activity was assessed biweekly using the Xenogen IVIS 100 Imaging System (Xenogen Corporation), by recording the bioluminescent signal emitted from the xenografted tumors. Starting 1 week after tumor transplantation, mice were injected intraperitoneally with 50 mg/kg firefly D-luciferin (Xenogen), 100 mg/kg ketamine, and 10 mg/kg xylazine hydrochloride (both from Sigma) in phosphate-buffered saline. Mice were photographed 10 minutes after injection of D-luciferin (Xenogen) on the IVIS 100 system (Xenogen) with an exposure time of 30 seconds. Images were quantified using Living Image software (Xenogen).
Magnetic Resonance Imaging
Because of animal handling protocols at our institution that prohibit the return of animals after transport outside the animal facility, it was necessary to kill the mice for MR brain imaging. The mice were imaged for intracranial BLI 1 day before they underwent MR imaging. Contrast-enhanced MR images of the mice brains were accomplished with the administration of 100 l of Gd via tail vein injection 5 minutes before they were killed by an overdose of intraperitoneal phenobarbital. Each mouse was centered in a radiofrequency wrist coil and imaged with T1-and T2-weighted 1-mm imaging sequences in axial, coronal, and sagittal planes on a 3-T magnet (Siemens). Total imaging time for each mouse was 15 minutes. Because MR imaging revealed ellipsoid-shaped tumors, tumor volume was calculated using the formula for ellipsoidal volume, as described by others. 8 To calculate tumor volume, we measured the radii of each tumor in 3 orthogonal planes (a, b, and c) on MR imaging and then used them in the ellipsoidal volume formula [volume = (4/3) abc]. 
Immunohistochemical Staining for Vimentin, EMA, GFAP, and MIB-1
Immunohistochemical stainings were on paraffin-fixed tissue slides cut at 4 m and then melted at 55-60°C for 30 minutes, deparaffinized in xylene for 5 minutes, and rehydrated in graded alcohols (washed twice each with 100% and 95% alcohol, and once with 70% alcohol) for 1 minute each. The following steps were performed on the Ventana ES (Ventana Medical Systems) at 40°C. Heat-induced epitope retrieval was applied in citrate buffer (pH 6.0) in a microwave oven for 15 minutes at half power, and allowed to cool for 15 minutes for tissue stained for vimentin, EMA, GFAP, and Ki 67 (MIB-1). The primary antibodies were applied for 32 minutes as follows: vimentin (1:300, mouse monoclonal Ab, Clone Vim 3B4, Dako Cytomation); EMA (1:200, mouse monoclonal Ab, Clone E29, Dako Cytomation); GFAP (1:400, mouse monoclonal Ab, Clone 6F2, Dako Cytomation); Ki 67 (1:160, mouse monoclonal Ab, Dako) followed by the appropriate secondary antibody for 8 minutes (Mouse Fab [1:200, mouse immunoglobulin G, Dako Cytomation]). Detection was done using the IView DAB Detection Kit (Ventana) and the counterstain was done with hematoxylin (Ventana) for 4 minutes. Slides were then dehydrated through graded alcohols (once in 70%, and twice each with 95% and 100%) for 30 seconds each, dehydrated in alcohol and xylene, and covered with a coverslip. Positive controls consisted of staining normal skin, normal pancreatic, brain, and colon cancer cells for vimentin, EMA, GFAP, and Ki 67, respectively. Negative controls were accomplished by running the above positive control tissue tests without the primary antibody.
The Ki 67 (MIB-1) proliferate index was obtained by taking 3 random pictures of each slide at ϫ 400 magnification using an Olympus Microfire camera. The images were analyzed using Image-Pro Plus 5.0 graphic analysis software. The MIB-1 index was calculated as the number of MIB-1-stained cells divided by the total number of cells stained.
Transmission Electron Microscopy for Desmosomes
Mouse tumor samples were harvested, cut into 1-mm 3 blocks, and fixed in 2.5% paraformaldehyde with 1% glutaraldehyde. After at least 24 hours of fixation, samples were rinsed twice for 10 minutes each in 0.1 M sodium cacodylate buffer with sucrose and calcium chloride at pH 7.4. This was followed by postfixing in 2% osmium tetroxide in 0.1 M sodium cacodylate buffer for 45 minutes at room temperature on a rotator. Samples were then rinsed in distilled water for 5 minutes and stained en bloc in aqueous uranyl acetate for 45 minutes at room temperature on a rotator. Samples were dehydrated with increasing alcohol concentrations (50-100%) at room temperature on a rotator. Cells were infiltrated with and then embedded in Spurr plastic. Thin sections were cut on a Leica UCT Ultramicrotome with a Diatome diamond knife, stained with uranyl acetate and Reynolds lead citrate, and examined on a Hitachi H7100 transmission electron microscope at 75 KV. Photographs were taken on Kodak 4489 film.
Statistical Analysis
The CH-157-MN-LucNeo skull base tumor volumes were calculated on MR imaging and compared with BLI-determined values. Comparisons were analyzed and 95% confidence intervals were generated using the two-tailed Spearman correlation test (GraphPad Prism 4.0) with statistical significance set at a probability value Ͻ 0.05. The curve fit was calculated using a nonlinear regression analysis with exponential growth equation. Mean values are presented Ϯ standard deviations.
Results
Characterization of the CH-157-MN and IOMM-Lee cell lines
The CH-157-MN and IOMM-Lee cell lines were chosen because of their ability to induce mouse flank tumors that resemble meningiomas. 17 The CH-157-MN immortal cell line was originally obtained from a 55-year-old woman in 1995, and analysis of cells grown in vitro show karyotypic changes typical of meningiomas (Table 1) . 10, 22 In 1990, Dr. Wei-Hwa Lee 9 described his intraosseous malignant meningioma cell line (IOMM-Lee), obtained from a WHO III lesion in a 61-year-old man. Electron microscopy on cells grown in vitro shows karyotypical and ultrastructural features that still fit its initial description of prominent nucleoli, intermediate filaments, and sparse microvilli on the cellular surface (Table 1) . 9, 10, 17 Our previous work with CH-157-MN-and IOMM-Lee-induced mouse flank tumors shows microscopic, immunohistochemical, and ultrastructural features consistent with meningiomas.
10,17
Stable Expression of Firefly Luciferase in CH-157-MNLucNeo and IOMM-Lee-LucNeo
For both the CH-157-MN and IOMM-Lee immortal cell lines, stable transfection with pMMP-LucNeo was obtained. These cells, CH-157-MN-LucNeo and IOMM-LeeLucNeo, were harvested during logarithmic growth and transplanted intracranially into mice.
In Vitro Growth Kinetics
Native CH-157-MN and transduced CH-157-MN-LucNeo cells showed similar doubling times of ~ 30 hours. Native IOMM-Lee and transduced IOMM-Lee-LucNeo cells had doubling times of ~ 30 hours. No significant difference was noticed between the growth rates of native immortal cell lines and LucNeo-transfected cell lines.
Tumor Induction and Intraoperative Death
First, we xenografted CH-157-MN-LucNeo meningioma cells at the skull base at varying cell concentrations. The overall intraoperative mortality was 11% (5 of 45 mice), with a tumor induction rate of 90% (36 of 40 procedures). The animals were killed 16-24 days later when they appeared sickly (exhibiting symptoms of dehydration and neurological deficits, for example). In general, the lower the transplanted cell number, the longer it took for the animals to become symptomatic. For example, the group with the lowest number of cells xenografted, 10 4 cells/animal, had the longest observation period (23 days; Fig. 1A) . Interestingly, these animals did not exhibit measurable bioluminescence values until Day 11, which explains the latency in data collection (Fig. 1A) . Next, we xenografted IOMM-Lee-LucNeo meningoma cells at the skull base at varying cell concentrations (Fig. 1B) . Out of 15 mice there was 1 operative death (7%), with an overall tumor induction rate of 100%. Animals were killed by Day 14 under the same criteria as above. Finally, we xenografted CH-157-MN-LucNeo meningioma cells overlying the cerebral convexities at varying cell concentrations. There were no operative deaths, and an overall tumor induction rate of 90% (9 of 10 cases) (Fig. 1C) . Animals were examined and killed at 17 and 23 days after xenografting.
Bioluminescence (Radiance) and Tumor Volume (MR Imaging)
Bioluminescence values for both CH-157-MN-LucNeo and IOMM-Lee-LucNeo intracranial tumors increased in a logarithmic fashion over time ( 
Autopsy Results and Histological, Immunohistochemical, and Ultrastructural Findings
Autopsy of CH-157-MN-LucNeo skull base tumors revealed discrete tumors that easily separated from adjacent brain but insinuated themselves along the skull base (Fig.  3) . Bioluminescence imaging of explanted tumors, mice skulls, and brains showed radiance from the tumor and the skull base directly underlying the tumor but not the brain (Fig. 3) . Autopsy of IOMM-Lee-LucNeo skull base tumors revealed soft, diffuse tumors that had insinuated along the skull base and cranial nerves.
Intracranial CH-157-MN-LucNeo and IOMM-Lee-LucNeo skull base tumors exhibited histological, immunohistochemical, and ultrastructural features consistent with meningioma (Fig. 4) . Microscopically, the skull base tumors grew along the skull base between the brain and bone, along cranial nerves, and into the Virchow-Robin spaces ( Fig. 4A and C-E) . Immunohistochemically, CH-157-MNLucNeo and IOMM-Lee-LucNeo tumors were vimentinpositive, EMA-negative, and GFAP-negative (Fig. 4F) .
The MIB-1 stainings demonstrated mean proliferative rates of 64 Ϯ 2% and 36 Ϯ 3% for CH-157-MN-LucNeo and IOMM-Lee-LucNeo tumors, respectively (Fig. 4G) . Electron microscopy of CH-157-MN-LucNeo and IOMM-LeeLucNeo exhibited desmosomes and junctional complexes, key ultrastructural features of meningiomas (Fig. 4H) (2)(p11.2), add (5)(p13), add (6)(p13), i(7)(p10)x2, add (9) (q21), add (12) (q21), Ϫ17, add (14)(q13), add (19) , add ( 
Discussion
This animal model for intracranial meningioma overcomes the main obstacle in studying these lesions by enabling sequential noninvasive tumor measurement in a costeffective manner. Previously, our lab has taken advantage of the mouse flank model of meningiomas because of the ease of assessing tumor size during treatments and the low cost of the procedure. 6, 7, 16 However, other investigators have reported difficulty in replicating our Matrigel augmentation flank model (RL Jensen, personal observation), and have pointed out the unnatural extracranial location of flank meningiomas. 16 The intracranial model in the present study offers ease of serial measurements and recapitulates the macroscopic, microscopic, immunohistochemical, and ultrastructural features of aggressive meningiomas.
Advantages and Disadvantages of the Mouse Model of Intracranial Meningioma With BLI
An intracranial meningioma model has the advantage of enabling researchers to study these tumors in their natural microenvironment. Serial measurements of growth or treatment effects are easily performed and do not interfere with intrinsic tumor biology. Bioluminescence enables intracranial tumor size assessment in a cost-effective manner. 21 In considering the overall cost of performing either MR imaging or BLI at our institution, BLI is less expensive. Assuming that the initial purchase of either imaging system has been made, and that the cost of processing mice for imaging is similar in either case because both require anesthesia and intravenous contrast injection, then the cost savings becomes apparent when considering time spent per scan (15 minutes for MR imaging compared with 5 minutes for BLI), the number of mice per scan (1 mouse compared with 5 mice), and machine operating fees (~ $1000/hour for MR imaging compared with ~ $100/hour for BLI). The overall cost of performing MR imaging in 30 mice is $ 7500 in a process that takes 7.5 hours (30 mice ϫ $1000/ hour ϫ 15 minutes/scan divided by 1 mouse/scan), whereas each BLI costs ~ $50 and takes 0.5 hours (30 mice ϫ $100/hour ϫ 5 minutes/scan divided by 5 mice/scan).
This system has the disadvantage of requiring stable transfection of a constitutively expressing bioluminescent enzyme into a given cell line to be studied. Given the difficulty of growing human operative specimens in vitro and successfully transplanting them in vivo, the added step of viral transfection with luciferase may prove difficult. 
The Intracranial Model Recapitulates the Histological, Immunohistochemical, and Ultrastructural Features of Meningiomas
All meningiomas grown in mouse intracranial locations showed histological, immunohistochemical, and ultrastructural features consistent with meningiomas. Histologically, meningiomas grown in mouse intracranial locations shared the histological features of aggressive tumor subtypes by insinuating along arachnoidal planes, cranial nerves, Virchow-Robin spaces, and occasionally invading the brain. 3, 10 Immunohistochemically, the hallmark of meningiomas is positive staining for vimentin and negative staining for GFAP, with roughly 80% staining for EMA. 3, 10 Mouse intracranial tumors showed 100% vimentin immunoreactivity and were negative for both EMA and GFAP. Finally, ultrastructurally CH-157-MN-LucNeo meningiomas grown in mouse skull base locations exhibited desmosomes and junctional complexes consistent with meningioma.
1,3 The IOMM-Lee-LucNeo skull base meningiomas also exhibited junctional complexes consistent with meningiomas. 1 
Optimization of the Intracranial Model of Meningiomas in Mice
On the basis of the experiments and results reported here,
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Mouse model of intracranial meningioma 309 the following recommendations may help to ensure optimal intracranial tumor xenografting. It appears that both a skull base and convexity model is possible. Slow infusion of the cell mix into intracranial locations and slow withdrawal minimizes brain trauma and cell leakage along the needle track, respectively. For skull base tumor induction, we favor 10 4 cells/animal because of longer survival times. For convexity tumors we recommend 5 ϫ 10 5 cells. To address the reduction of luminescence as photons travel through tissues of varying densities, we recommend comparing control and treatment groups from the same transplant location (skull base controls with skull base treatments). Szentirmai et al. 21 measured the luminescence of 10 5 U87-LucNeo glioma cells both in vitro and in vivo, showing a signal reduction of log 2.65 after intracranial implantation into the mouse striatum. This reduction of luminescence as photons travel through tissues limits the comparison of control and treatment groups to tumors implanted in the same location.
Conclusions
Noninvasive BLI enabled successful imaging of intracranial meningiomas in mice induced by the implantation of CH-157-MN-LucNeo and IOMM-Lee-LucNeo meningioma cell lines. The resulting tumors exhibited the biological growth behavior and microscopic features of aggressive human meningiomas. This novel bioluminescence intracranial meningioma model in mice enables the study of adjuvant therapies on meningiomas in their natural location in a cost-effective and efficient manner.
